Artemis Therapeutics Inc.
Artemis Therapeutics Inc. (ATMS) Insider Trading
Form 4 buy vs sell counts, ratio, and sentiment — switch this quarter or last 12 months; chart and transactions below.
SEC EDGAR · FMP · ATMS · as of Jun 9, 2026
Activity summary
Buy transactions
0
P-Purchase only
Sell transactions
1
12 Months
Buy/Sell ratio
0.00
Buy/Sell (by trades)
Overall sentiment
Artemis Therapeutics Inc. insiders have been primarily selling shares over the past 12 Months. Selling activity is often driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment toward the company.
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · Buy = P-Purchase only · Sell = S-Sale only
As of Jun 9, 2026
ATMS insider buying and selling by quarter
ATMS insider selling · ATMS insider buying stocks · quarterly insider activity
Mobile shows last 4Q · Desktop shows full 8Q
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · last 8 quarters
As of Jun 9, 2026
Recent insider transactions
ATMS executive sell shares · ATMS board member insider trading · ATMS insider trading SEC filing
Scroll horizontally to see all columns
| Date | Insider | Type | Shares | Value | Filing |
|---|---|---|---|---|---|
| Dec 18, 2018 | Peleg Gadi Director | Sale | 182 | $47 | Form 4 |
| Oct 23, 2017 | Culley Brian M CEO | Purchase | 25,000 | $25K | Form 4 |
| Jun 26, 2017 | Wolf Dana Chief Scientific Officer | Option | 35,202 | $352 | Form 4 |
| Jan 25, 2012 | Gilat Tal President and CEO | Award | 2,055,604 | — | Form 4 |
| Mar 3, 2011 | Schoenheimer Pierre Lucien Director | Sale | 10,000 | $2K | Form 4 |
| Mar 2, 2011 | Peleg Gadi Chairman of the Board · Director | Award | 277,778 | $50K | Form 4 |
| Mar 2, 2011 | Raich Alon Director | Award | 62,500 | $11K | Form 4 |
| Mar 2, 2011 | Bettsak Jonathan Director | Award | 48,611 | $9K | Form 4 |
| Mar 2, 2011 | Schoenheimer Pierre Lucien Director | Award | 62,500 | $11K | Form 4 |
| Mar 2, 2011 | SASS DAVID W Secretary · Director | Award | 62,500 | $11K | Form 4 |
| Oct 15, 2010 | Schoenheimer Pierre Lucien Director | Sale | 45,000 | $7K | Form 4 |
| Oct 18, 2010 | Schoenheimer Pierre Lucien Director | Sale | 19,000 | $3K | Form 4 |
| Mar 11, 2010 | Peleg Gadi Chairman ot the Board · Director | Purchase | 1,600,000 | $200K | Form 4 |
| Mar 11, 2010 | Raich Alon Director | Purchase | 200,000 | $25K | Form 4 |
| Mar 11, 2010 | MEERFELD YARON COO · Director | Purchase | 800,000 | $100K | Form 4 |
| Mar 11, 2010 | Schoenheimer Pierre Lucien Director | Purchase | 2,000,000 | $250K | Form 4 |
| Mar 30, 2007 | Schoenheimer Pierre Lucien Director | Purchase | 25,000 | $48K | Form 4 |
| Mar 30, 2007 | ICTS INTERNATIONAL N V 10 percent owner | Sale | 155,000 | $295K | Form 4 |
| Dec 12, 2006 | HOUSMAN ELIE Chairman and CEO · Director | Gift | 7,000 | — | Form 4 |
Wolf Dana
Chief Scientific Officer
Date
Jun 26
Shares
35,202
Price
$0.01
Value
$352
Peleg Gadi
Chairman of the Board · Director
Date
Mar 2
Shares
277,778
Price
$0.18
Value
$50K
Schoenheimer Pierre Lucien
Director
Date
Mar 2
Shares
62,500
Price
$0.18
Value
$11K
Schoenheimer Pierre Lucien
Director
Date
Oct 15
Shares
45,000
Price
$0.15
Value
$7K
Schoenheimer Pierre Lucien
Director
Date
Oct 18
Shares
19,000
Price
$0.15
Value
$3K
Peleg Gadi
Chairman ot the Board · Director
Date
Mar 11
Shares
1,600,000
Price
$0.13
Value
$200K
MEERFELD YARON
COO · Director
Date
Mar 11
Shares
800,000
Price
$0.13
Value
$100K
Schoenheimer Pierre Lucien
Director
Date
Mar 11
Shares
2,000,000
Price
$0.13
Value
$250K
Schoenheimer Pierre Lucien
Director
Date
Mar 30
Shares
25,000
Price
$1.90
Value
$48K
ICTS INTERNATIONAL N V
10 percent owner
Date
Mar 30
Shares
155,000
Price
$1.90
Value
$295K
▸ Source: SEC EDGAR · Form 4 filings · ⚡ = value ≥ $1M · Award/Option price shows —
About ATMS insider trading
ATMS insider trades
Artemis Therapeutics Inc. (ATMS) insider trading data is sourced from SEC Form 4 filings submitted by corporate insiders, including ATMS. Over the past 12 months, 0 insiders have filed transactions with the SEC. ATMS insiders have been primarily selling, which may reflect pre-scheduled Rule 10b5-1 plan executions.
For Artemis Therapeutics Inc.'s institutional ownership breakdown and insider ownership percentage, see the Ownership tab → Ownership tab →
Frequently asked questions
ATMS insider trading · 5 questionsThe insiders of Artemis Therapeutics Inc. (ATMS) include executives and directors such as ATMS, among others. Over the past 12 months, 0 insiders have filed Form 4 transactions with the SEC. Insider transactions are required to be reported within 2 business days of the trade date.
▸ Source: FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · acquisitionOrDisposition A=Buy, D=Sell · RSU vesting (M-Exempt) excluded from sentiment bar · As of Jun 9, 2026